Showing results (111-120 of 366) with videos related to

Sort By:
Pageof 37
Cancer|October 15, 2008
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007Gordon F Schwartz, Kevin S Hughes, Henry T Lynch, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.
The Lancet. Oncology|July 10, 2022
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A Reiss, Rosemarie Mick, Ursina Teitelbaum, et al.
Frontiers in Cardiovascular Medicine|March 4, 2022
BRCA1/2 Mutations and Cardiovascular Function in Breast Cancer SurvivorsBiniyam G Demissei, WenJian Lv, Nicholas S Wilcox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2010
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cellsRobert H Vonderheide, Patricia M LoRusso, Magi Khalil, et al.
Plos One|August 23, 2019
Correction: Genome-wide association analysis of HDL-C in a Lebanese cohortRebecca Deek, Jason Nasser, Anthony Ghanem, et al.
Plos One|June 19, 2019
Genome-wide association analysis of HDL-C in a Lebanese cohortRebecca Deek, Jason Nasser, Anthony Ghanem, et al.
JAMA Network Open|August 5, 2025
Racial Differences in Screening Eligibility by Breast Density After State-Level Insurance ExpansionMattia A Mahmoud, Sarah Ehsan, Sara P Ginzberg, et al.
JCO Precision Oncology|July 28, 2018
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationRachna T Shroff, Andrew Hendifar, Robert R McWilliams, et al.
The New England Journal of Medicine|June 6, 2017
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationMark Robson, Seock-Ah Im, Elżbieta Senkus, et al.
Pageof 37